Skip to content
HomeLatest newsAcuvue Oasys® with Transitions™ Light Intelligent Technology™ contact lenses named one of Time’s Best Inventions of 2018
Eyes showing how contact lenses respond to changing light conditions via a photochromic filter

Acuvue Oasys® with Transitions™ Light Intelligent Technology™ contact lenses named one of Time’s Best Inventions of 2018

This first-of-its-kind innovation has a dynamic photochromic filter that responds to changing light conditions.

Picture this: You pop in your contact lenses before heading outside on a sunny day and don’t immediately squint—because your lenses have automatically darkened to filter out the bright light, seamlessly keeping your eyes comfortable and your vision crisp.

Sounds futuristic, right?

Not anymore, with the development of Acuvue Oasys® with Transitions™ Light Intelligent Technology™. And while the product won’t be available until the first half of 2019, it’s already causing a stir: The contact lenses were just chosen as one of Time‘s Best Inventions of 2018.

Better sight through Light Intelligent Technology

Inset- Acuvue Oasys News Item- Acuvue Oasys Contact lens

A photochromic filter allows the lens to respond to changes in light and darken accordingly (shown left to right)

Each year, Time seeks out lifestyle innovations that carry the promise of making the world, in their words, “better, smarter and even a bit more fun.” You can check out last year’s winners here.

The revolutionary Acuvue Oasys with Transitions Light Intelligent Technology lenses experience fits the bill, thanks to a dynamic photochromic filter that responds to changing light conditions—indoors and out—by reducing exposure to bright light, filtering out blue light, blocking UV rays and, of course, providing vision correction at the same time. (Learn more about Acuvue, including safety information.)

We believe it will redefine how people think about wearing contact lenses, and we are excited to see the world react to this first-of-its-kind innovation.
Ashley McEvoy

It’s the brainchild of a partnership between Johnson & Johnson Vision Care, Inc. and Transitions Optical—the leading provider of photochromic smart adaptive eyeglass lenses worldwide. In April of this year, the lenses were cleared by the U.S. Food and Drug Administration (FDA) as the first to be invented with light adaptive technology.

“The introduction of Acuvue Oasys with Transitions Light Intelligent Technology has been 15-plus years in the making, and its distinction as a Time Best Invention of 2018 is incredibly meaningful to the many researchers, scientists, engineers and others who have seen the product from its initial concept,” says Ashley McEvoy, Executive Vice President, Worldwide Chairman, Medical Devices, Johnson & Johnson. “We believe it will redefine how people think about wearing contact lenses, and we are excited to see the world react to this first-of-its-kind innovation.”

Considering getting contacts?

Check out this new wearer guide, packed with great tips for safely and comfortably using contact lenses.

More from Johnson & Johnson

Meet the medical engineer behind the innovative heart pump that revolutionized cardiac health

Drawing on his fascination with airplane technology, Thorsten Siess, Ph.D., came up with an idea that became the Impella heart pump. Now, 25 years since it entered the market, this groundbreaking device has helped more than 330,000 patients recover from heart injuries.

What you need to know about Johnson & Johnson’s 2024 third quarter earnings

Check out this infographic breakdown of the company’s third quarter performance, with highlights from its Innovative Medicine and MedTech businesses.

What is a rheumatic disease?

More than 200 conditions are classified as rheumatic diseases, including rheumatoid arthritis, lupus and Sjögren’s disease. They tend to affect the joints and connective tissues, causing pain and swelling and impacting quality of life. Here’s what a doctor wants you to know about the different types, symptoms and risk factors—and how Johnson & Johnson is innovating new treatments.